Sermorelin, GHRP-2
Sermorelin combined with GHRP-2 creates a dual-mechanism growth hormone amplification stack where Sermorelin acts as the “on switch” via GHRH receptor activation to trigger GH production and release, while GHRP-2 acts as the “volume knob” via ghrelin receptor agonism to amplify the pituitary’s GH response and frequency—together producing 10-20 fold higher GH elevation than either peptide alone.
Route
Subcutaneous injection
Dose range
100 mcg – 200 mcg
Frequency
1–2 times daily
Cycle length
12–16 weeks
Overview
Sermorelin combined with GHRP-2 creates a dual-mechanism growth hormone amplification stack where Sermorelin acts as the “on switch” via GHRH receptor activation to trigger GH production and release, while GHRP-2 acts as the “volume knob” via ghrelin receptor agonism to amplify the pituitary’s GH response and frequency—together producing 10-20 fold higher GH elevation than either peptide alone.
The synergy derives from complementary pathways: Sermorelin sustains GH signaling through natural circadian channels while GHRP-2’s appetite-stimulating properties support caloric surplus for bulking phases. Users report dramatic lean mass gains, fat loss during cutting cycles, enhanced recovery, improved sleep quality, elevated libido, and strengthened collagen production supporting joint health. Dosing typically involves daily injections timed to natural GH windows (bedtime or post-workout) for maximum pituitary responsiveness. For aggressive muscle building, competitive athletes, or therapeutic GH restoration, Sermorelin/GHRP-2 delivers pharmaceutical-grade GH benefits through natural physiologic stimulation.
Studied benefits
- This combination provides a robust, pulsatile release of Growth Hormone
- It is effective for improving lean body mass, accelerating recovery from training, and enhancing deep-sleep quality
- The addition of GHRP-2 provides a more potent GH spike than Sermorelin alone
Reported side effects
- Common side effects include a temporary increase in appetite and mild water retention
- Users may experience transient facial flushing or a slight "head rush" shortly after injection
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
| Tier | Dose (mcg) | Draw at 2.5 mg/mL | Log |
|---|---|---|---|
| Anti-Aging Research | 100 mcg Each | 4 units (0.04 mL) | + Log |
| Recovery Focus | 200 mcg Each | 8 units (0.08 mL) | + Log |
Frequency
1–2 times daily.
Timing
Bedtime on an empty stomach (3 hours post-meal) is the primary research standard.
Cycle length
12–16 weeks.
Unit calculator
Set your vial and water; the table above updates.
2.5 mg/mL
50 doses of 100 mcg per vial
At the starting dose (100 mcg × 7/week for a 12-week cycle) you would use about 8.4 mg, i.e. 2 × 5 mg vials. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Maintain a high-protein, balanced diet to provide the necessary substrate for increased protein synthesis and tissue repair triggered by the growth hormone pulses. Incorporate both resistance training and cardiovascular exercise to capitalize on the anabolic and lipolytic synergy of the combined GHRH analog and GHRP-2. Ensure 7–9 hours of quality sleep, as these peptides work most effectively when synchronized with the natural nocturnal growth hormone cycles. Adhere to strict fasting—no food for 2 hours before and 30 minutes after administration—to prevent insulin from blunting the pituitary gland’s secretory response.
Evidence
Research summaries
Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels
Findings: Dramatically increases IGF-1 (a marker of growth hormone activity), boosts testosterone and free testosterone levels, improves lean muscle mass, and burns fat without disrupting natural hormone balance in healthy adults seeking fitness improvements.
This real-world study followed 14 healthy men taking the combination of GHRP-2 (100 micrograms), GHRP-6 (100 micrograms), and sermorelin (100 micrograms) three times daily via injection. After an average of 134 days, their IGF-1 levels jumped from 159.5 to 239.0 ng/mL—a huge 50% increase. Even better, their testosterone and free testosterone both climbed significantly after 90 days of treatment. The study showed that when you use pulsatile (on-and-off) hormone stimulation rather than constant synthetic injection, your body stays healthier. A key finding: men on estrogen-blocking drugs still got IGF-1 boosts, just smaller ones, proving the combo works through multiple body pathways. This is like your body's natural dimmer switch versus fluorescent lights—more natural, more controlled, and safer long-term. No serious side effects appeared in any patient, though some experienced temporary appetite increases.
Read the study ↗The Safety and Efficacy of Growth Hormone Secretagogues (focusing on GHRP-2 synergy with sermorelin-like agents)
Findings: Increases growth velocity in short children (5–8 cm/year), stimulates natural appetite to help weight gain in eating disorders, restores growth hormone in critical illness, and builds lean muscle while trimming fat in adults.
This comprehensive review analyzed 30+ human studies of growth hormone secretagogues. Key findings for GHRP-2: when given to 15 children with short stature at doses of 5–15 micrograms per kilogram twice or three times daily, six of them stayed on the medication for 18–24 months and sustained an impressive average growth speed of 6.0 centimeters per year—nearly double normal childhood growth rates. In adults with severe anorexia nervosa, GHRP-2 triggered such strong appetite signals that one patient gained 6.7 kilograms over 14 months and reported feeling less full too quickly, a major breakthrough for people struggling with eating disorders. In hospital patients with serious illness (surgery, trauma, critical care), GHRP-2 infusions for just five days brought growth hormone and IGF-1 back to normal levels, reversing the hormone collapse that happens during extreme stress. The review noted that because GHSs trigger your body's own pituitary gland rather than injecting synthetic hormone, feedback mechanisms (controlled by the hormone somatostatin) stay intact, preventing overdose. Side effects were minimal: transient appetite boost and a temporary blip in cortisol (the stress hormone), both vanishing quickly. Glucose control was the only lingering concern in some patients—fasting blood sugar edged up in a few cases. This proves that pairing sermorelin (GHRH-like) and GHRP-2 (ghrelin-like) hits multiple growth hormone triggers simultaneously, making it far more effective than either drug solo.
Read the study ↗Sermorelin: A Better Approach to Management of Adult-Onset Growth Hormone Insufficiency?
Findings: Reverses aging-related growth hormone decline in adults, builds lean body mass, improves bone density, boosts energy and mood, and mimics youthful hormone patterns without cancer risks tied to synthetic hormone injections.
Dr. Richard Walker's review explains why sermorelin is superior to synthetic growth hormone for aging adults. Sermorelin stimulates your own pituitary gland to manufacture endogenous (your own) growth hormone, not inject fake hormone that floods your system. This matters hugely: sermorelin-triggered GH release stays episodic (pulses throughout the day) rather than constant, preventing the "square wave" flat high levels of synthetic hormone that can spark tumors or diabetes. Negative feedback loops—your body's safety system using somatostatin—stil
Read the study ↗More references (5)
- Growth Hormone Secretagogues in the Management of Body Composition, 2025
- Sermorelin Tri-Blend (Sermorelin/GHRP-2/GHRP-6) Clinical Efficacy Report, 2024
- Synergistic Effects of GHRH Analogs and GHRPs on Pituitary GH Release, 2023
- Sermorelin Acetate and GHRP-2: Combination Therapy for IGF-1 Optimization, 2021
- Comparison of Sermorelin and GHRP-6 in Growth Hormone Stimulation, 2006
Identification
Chemistry
- cas
- 158861-67-7
- formula
- C₁₄₉H₂₄₆N₄₄O₄₂S
- molecular weight
- 3357.9–3357.93 g/mol (free base); 3417.99 g/mol (acetate salt)
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
BPC-157, TB-500
- Route
- Subcutaneous
- Dose
- 333 mcg – 667 mcg
- Cycle
- 8–12 weeks
CJC-1295 (No DAC)
No DAC
- Route
- Subcutaneous
- Dose
- 1 mg – 2 mg
- Cycle
- 8–12 weeks